# A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia

Study · id `cardio:ct-nct03009487` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03009487](<https://clinicaltrials.gov/study/NCT03009487>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03009487

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 265 participants.

## Technical summary

Registry record NCT03009487. Randomized; double masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2018-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 265 participants (enrolled count; ClinicalTrials.gov record NCT03009487, source copy `cardio:ctgov-nct03009487-2022-01-11`, retrieved 2026-10-26)
- Started: 2017-01 (actual) (ClinicalTrials.gov record NCT03009487, source copy `cardio:ctgov-nct03009487-2022-01-11`, retrieved 2026-10-26)
- Primary completion: 2018-04 (actual) (ClinicalTrials.gov record NCT03009487, source copy `cardio:ctgov-nct03009487-2022-01-11`, retrieved 2026-10-26)
- Completion: 2018-04 (actual) (ClinicalTrials.gov record NCT03009487, source copy `cardio:ctgov-nct03009487-2022-01-11`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03009487, source copy `cardio:ctgov-nct03009487-2022-01-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03009487-2022-01-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia
- Condition: Hypertension
- Condition: Hyperlipidemias
- Intervention (Drug): Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg
- Intervention (Drug): Olmesartan 40 mg, Rosuvastatin 20mg
- Intervention (Drug): Amlodipine/Olmesartan 10/40mg (Combination drug)
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 87972eebbd1ae5805d161b4d05e572a4fa6897ecfab771d4c738330a0ce4bd84
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
